Cargando…
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632668/ https://www.ncbi.nlm.nih.gov/pubmed/37647601 http://dx.doi.org/10.1182/bloodadvances.2023010956 |
_version_ | 1785132629212790784 |
---|---|
author | Ravandi, Farhad Bashey, Asad Foran, James Stock, Wendy Mawad, Raya Short, Nicholas Yilmaz, Musa Kantarjian, Hagop Odenike, Olatoyosi Patel, Anand Garcha, Raman Ainsworth, William Barrett Clynes, Raphael Kanodia, Jitendra Ding, Ying Li, Huajiang Kye, Steve Mims, Alice |
author_facet | Ravandi, Farhad Bashey, Asad Foran, James Stock, Wendy Mawad, Raya Short, Nicholas Yilmaz, Musa Kantarjian, Hagop Odenike, Olatoyosi Patel, Anand Garcha, Raman Ainsworth, William Barrett Clynes, Raphael Kanodia, Jitendra Ding, Ying Li, Huajiang Kye, Steve Mims, Alice |
author_sort | Ravandi, Farhad |
collection | PubMed |
description | Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently binds both CD3 and CD123 to recruit cytotoxic T cells to kill CD123+ tumor cells. This phase 1 study’s primary objectives were safety and tolerability and identification of a maximum tolerated dose/recommended dose for use as monotherapy in patients with relapsed/refractory AML. Identification of a recommended phase 2 vibecotamab dose comprised 3 step-up doses (Week 1), which were noted to reduce cytokine response syndrome (CRS), followed by weekly dosing (1.7 μg/kg, Cohort -1D). In 16 of 120 patients, at least 1 treatment-emergent adverse event was classified as a dose-limiting toxicity. CRS, the most common adverse event (59.2%), managed with premedication, were mostly ≤grade 2. A secondary objective was assessment of efficacy in patients with CD123-expressing leukemias. A total of 10 of 111 (9.0%) efficacy-evaluable patients with AML achieved an overall response of morphologic leukemia-free state or better with an overall objective response rate (ORR) of 9.0%. Response was only observed in patients receiving a target dose of 0.75 μg/kg or higher (n = 87) in which the efficacy-evaluable ORR was 11.5%. Response was associated with lower baseline blast counts in blood and bone marrow (<25%) suggesting potential benefit. This trial was registered at www.clinicaltrials.gov as #NCT02730312. |
format | Online Article Text |
id | pubmed-10632668 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-106326682023-11-10 Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia Ravandi, Farhad Bashey, Asad Foran, James Stock, Wendy Mawad, Raya Short, Nicholas Yilmaz, Musa Kantarjian, Hagop Odenike, Olatoyosi Patel, Anand Garcha, Raman Ainsworth, William Barrett Clynes, Raphael Kanodia, Jitendra Ding, Ying Li, Huajiang Kye, Steve Mims, Alice Blood Adv Clinical Trials and Observations Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently binds both CD3 and CD123 to recruit cytotoxic T cells to kill CD123+ tumor cells. This phase 1 study’s primary objectives were safety and tolerability and identification of a maximum tolerated dose/recommended dose for use as monotherapy in patients with relapsed/refractory AML. Identification of a recommended phase 2 vibecotamab dose comprised 3 step-up doses (Week 1), which were noted to reduce cytokine response syndrome (CRS), followed by weekly dosing (1.7 μg/kg, Cohort -1D). In 16 of 120 patients, at least 1 treatment-emergent adverse event was classified as a dose-limiting toxicity. CRS, the most common adverse event (59.2%), managed with premedication, were mostly ≤grade 2. A secondary objective was assessment of efficacy in patients with CD123-expressing leukemias. A total of 10 of 111 (9.0%) efficacy-evaluable patients with AML achieved an overall response of morphologic leukemia-free state or better with an overall objective response rate (ORR) of 9.0%. Response was only observed in patients receiving a target dose of 0.75 μg/kg or higher (n = 87) in which the efficacy-evaluable ORR was 11.5%. Response was associated with lower baseline blast counts in blood and bone marrow (<25%) suggesting potential benefit. This trial was registered at www.clinicaltrials.gov as #NCT02730312. The American Society of Hematology 2023-09-01 /pmc/articles/PMC10632668/ /pubmed/37647601 http://dx.doi.org/10.1182/bloodadvances.2023010956 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical Trials and Observations Ravandi, Farhad Bashey, Asad Foran, James Stock, Wendy Mawad, Raya Short, Nicholas Yilmaz, Musa Kantarjian, Hagop Odenike, Olatoyosi Patel, Anand Garcha, Raman Ainsworth, William Barrett Clynes, Raphael Kanodia, Jitendra Ding, Ying Li, Huajiang Kye, Steve Mims, Alice Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia |
title | Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia |
title_full | Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia |
title_fullStr | Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia |
title_full_unstemmed | Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia |
title_short | Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia |
title_sort | phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia |
topic | Clinical Trials and Observations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632668/ https://www.ncbi.nlm.nih.gov/pubmed/37647601 http://dx.doi.org/10.1182/bloodadvances.2023010956 |
work_keys_str_mv | AT ravandifarhad phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT basheyasad phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT foranjames phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT stockwendy phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT mawadraya phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT shortnicholas phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT yilmazmusa phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT kantarjianhagop phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT odenikeolatoyosi phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT patelanand phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT garcharaman phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT ainsworthwilliambarrett phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT clynesraphael phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT kanodiajitendra phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT dingying phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT lihuajiang phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT kyesteve phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia AT mimsalice phase1studyofvibecotamabidentifiesanoptimizeddosefortreatmentofrelapsedrefractoryacutemyeloidleukemia |